» Articles » PMID: 39006080

Causal Associations of BAFF-R on IgD+ CD24- B Cell Immune Cell Trait with Hepatocellular Carcinoma and the Mediating Role of Phenylacetylglutamate Levels: a Mendelian Randomization Study

Overview
Journal J Cancer
Specialty Oncology
Date 2024 Jul 15
PMID 39006080
Authors
Affiliations
Soon will be listed here.
Abstract

We conducted a bi-directional two-sample Mendelian randomization (MR) analysis to investigate the causal associations between immune cell traits and hepatocellular carcinoma (HCC) and identified the mediating factor of metabolites. The exposure factors were immune cell traits, the mediators were metabolites, and the outcome variable was HCC. Inverse-variance weighted method (IVW) was the main method. Weighted median, MR-Egger regression, weighted mode, simple mode, and MR pleiotropy residual sum and outlier (MRPRESSO) methods were used as complementary methods. The results were tested by using the Bayesian weighted Mendelian randomization (BWMR) approach in our MR study. Subsequently, the potential mediating effect was investigated by conducting a two-step mediation analysis. We identified 26 traits with suggestive correlations between immune cell traits and HCC, with 4 immune cell traits among them having causal correlations with HCC. There were no causal correlations between HCC and immune cell traits in the reverse MR analysis. In the mediation analysis, we found a positive causal association between B cell-activating factor receptors (BAFF-R) on IgD+ CD24- B cell and HCC [IVW: odd ratio (OR), 0.845; 95% CI, 0.759-0.942; p = 0.002]. Phenylacetylglutamate (PAG) levels mediated 7.353% of the causal pathway from BAFF-R on IgD+ CD24- B cell and HCC. In conclusion, BAFF-R on IgD+ CD24- B cell lowers risk of HCC, with PAG levels playing a mediating role.

Citing Articles

Causal effects and metabolites mediators between immune cell and risk of colorectal cancer: a Mendelian randomization study.

Yang Q, Duan B, Yue J, Zhang D, Chen X, Shi M Front Immunol. 2024; 15:1444222.

PMID: 39346920 PMC: 11428109. DOI: 10.3389/fimmu.2024.1444222.


Causal Effect of Immunocytes, Plasma Metabolites, and Hepatocellular Carcinoma: A Bidirectional Two-Sample Mendelian Randomization Study and Mediation Analysis in East Asian Populations.

Tang X, Xue J, Zhang J, Zhou J Genes (Basel). 2024; 15(9).

PMID: 39336774 PMC: 11431556. DOI: 10.3390/genes15091183.

References
1.
Lin J, Zhou J, Xu Y . Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis. Brain. 2023; 146(8):3364-3372. PMC: 10393411. DOI: 10.1093/brain/awad070. View

2.
Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H . Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma. Kurume Med J. 1996; 43(2):137-47. DOI: 10.2739/kurumemedj.43.137. View

3.
Hernandez S, Jakobsen M, Bak R . Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer Immunotherapy. Int J Mol Sci. 2022; 23(19). PMC: 9570010. DOI: 10.3390/ijms231911397. View

4.
Stine Z, Schug Z, Salvino J, Dang C . Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2021; 21(2):141-162. PMC: 8641543. DOI: 10.1038/s41573-021-00339-6. View

5.
Kulik L, El-Serag H . Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2018; 156(2):477-491.e1. PMC: 6340716. DOI: 10.1053/j.gastro.2018.08.065. View